THere is no documeted bennefit to taking a SERM (Evista is a type of drug called a selective estrogen receptor modulator) with a bisphosphonate (Reclast, Fosamax, Actonel). There have been multiple clinical trials conducted to study the possible synergy of adding a SERM with a bisphonate and there have never been any documented positive patient outcomes. You may consider switching to a bisphosphonate and discontinuing the SERM. Clinical evidence shows that EVISTA fails to improve patient outcomes (i.e. reducing fractures) anywhere except the spine. In their pivotal trials, which included over 7700 patients, Evista did not prevent fractures at the hip, wrist, leg, ankle or anywhere other than the spinal vertebrae.